Back to the registry
Agent passport

CuroSygnal

Curo 46 LLC · Intelligence & Research

SaaSNo attestation published

Certification per Microsoft Marketplace.

RehospitalizationAI Risk PredictionPAC
Provenance reach3 of 12 layers traced

Evidence tier Source Confirmed · 7 captures on record

User ratingNot rated0 reviews on the listing
Runs onSaaSSaaS
ProvenanceUnknown33% of the provenance layers this product can disclose
Evidence riskHighSign in to see the basis for this band.

What the publisher says

As described on Microsoft Marketplace.

Rehospitalizations drive Five-Star penalties, value-based purchasing risk, and post-acute margin compression. Many of them are predictable. CuroSygnal helps your team see the signals earlier.

CuroSygnal is clinical AI that surfaces residents with elevated risk indicators, 3 to 14 days before a potential admission. Your nurses see a short, prioritized list of the residents to review today, with the contributing clinical signals visible on every score.

Show the rest of the publisher’s description (28 more lines)

Many early-warning tools generate alert noise that clinical teams learn to tune out, eroding trust in the signals that need attention. CuroSygnal is engineered differently: high signal-to-noise, with feature-level explainability that supports independent clinician review on every output.

The result: your nurses see which residents have elevated risk indicators, and the contributing clinical signals behind each score. Clear explainability supports confident clinical direction; every clinical decision stays with the team.

CuroSygnal predicts return to the hospital 3 to 14 days in advance, with up to 98% accuracy. Trend forecasting provides a potential explanation of patient decline and the contributing "triggering" observations behind each score.

In practice: when a resident's risk score crosses threshold, the day-shift charge nurse opens Hot Rack, reviews the contributing clinical signals, and brings the case to the morning huddle, days before a potential admission.

What your team gets

  • Hot Rack ranked patient queue. Prioritized list of residents with elevated risk indicators, with the contributing clinical signals visible on every score.
  • Engineered for clinical precision. High signal-to-noise, so the care team can trust what surfaces.
  • 3 to 14 day forward-looking window. Lead time to review emerging risk signals before a potential admission.
  • Feature-level explainable AI. Every risk score is traceable to the contributing clinical signals, supporting independent clinician review.
  • Trend forecasting. Surfaces the contributing "triggering" observations behind a rising risk score.
  • Census, payer, and role-based views. Live operational visibility across single or multi-facility deployments.
  • Native to MatrixCare. Integrates with any EHR platform.
  • Microsoft sign-in. Authenticate with your Microsoft identity.

Performance metrics

  • Up to 98% accuracy on return-to-hospital prediction, 3 to 14 days in advance of admission.
  • Up to 98.5% AUC (threshold-independent discrimination).
  • Up to 98.7% sensitivity at the best operating threshold.

These figures reflect validation across multi-facility post-acute deployments.

Who it is built for

Built for the teams that carry rehospitalization risk: skilled nursing and post-acute networks, and the discharge teams inside acute hospitals.

Regulatory posture

CuroSygnal is a clinical decision support tool under the FDA CDS exemption (Sept 2022). Final clinical decisions remain with the licensed clinician.

Privacy and security

Demos run on Curo46-hosted fake patients and facilities. No PHI is exchanged in the sales cycle. Data is encrypted in transit and at rest. Business Associate Agreement (BAA) available for production deployment.

Book a 30-minute demo

The fastest way to evaluate CuroSygnal is to see the platform run on fake patients and facilities.

Book a demo →

Or email sales@ggenomics.com. Response within one business day.

Preview

1 image
CuroSygnal preview 1

Agent build and provenance

See the full provenance

The layer-by-layer build, the evidence behind each claim, the risk basis and the cross-marketplace links are open to any account. Some rows are disclosed, some the source leaves Unknown; a free account shows you which.

Compliance

Government
  • FedRAMPConfirmedNot listed90%, registry-checkedNo FedRAMP Marketplace entry matched this vendor's domain, checked 2026-08-27registry recordas observed 2026-08-27

Confirmed means matched to a public authoritative registry. Claimed means the vendor or its listing states it, not yet cross-checked. A framework not shown was not found in any source we hold, which is not evidence against it. Not listed means a scoped registry check found no match for this vendor's domain: a No is a scoped registry check, not a compliance judgment. Confidence bands: 95% domain-verified, 90% registry-checked, 80% self-attested, 70% weak signal. Self-attested items marked “vendor's site” are gathered from the vendor's own website and are not verified by us.

Sources

Marketplace listingmarketplace.microsoft.comSource
Privacy PolicyPrivacy PolicySource
License TermsLicense TermsSource

Publisher resources

3 links

Linked repositories

RepositoriesUnknownUnknown

Unknown means this listing does not publish a repository. It is not a statement that the code is closed, and a linked repository is not a claim that the publisher wrote it: the registry computes that relationship privately and does not publish it.

Pricing
Unknown
Not stated
Delivery
SaaS
https://intercom.help/general-genomics-inc/en/articles/15400982-curosygnal-support
Open the source listing ↗

Evidence risk is the share of the build you cannot see before you deploy, not a security rating. Sign in to see the layer-by-layer basis for this band.